News
-
March 2022: Krappmann lab identifies new inhibitory phosphorylation in lymphocytes and lymphoma
-
-
January 2022: Krappmann lab contributes to identification of human MALT1 variants.
-
December 2021: Krappmann lab contributes to MALT1 as driver in triple negative breast cancer.
-
December 2021: RU Krappmann receives Helmholtz Munich Best Paper Award.
-
November 2021: RU Krappmann solves in vivo function of MALT1-TRAF6 association.
-
-
July 2021: RU Krappmann/RU Plettenburg publish a patent review of MALT1 inhibitors.
-
-
-
-
October 2019: RU Krappmann identifies MALT1 regulation by phosphorylation.
-
-
-
February 2019: RU Krappmann contributes to study linking Hectd3 to pathogenic Th17 cell function.
-
November 2018: RU Krappmann uncovers mechanism of CBM signaling.
-
October 2018: RU Krappmann contributes to research on MALT1 protease activation.
-
About us
The Research Unit Cellular Signal Integration (AZS) at the Institute of Molecular Toxicology and Pharmacology (TOXI) conducts research for a better understanding of cellular response pathways. In doing so, it focuses on the interaction of proteins complexes and the effects of posttranslational modifications. The aim of this research is to understand the faulty regulation of the signal complexes in the immune system in case of infectious diseases and the development of lymphoma, and to attack this pharmacologically.
